Shots:

• The US FDA has approved the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin’s automated LIAISON XS platform
• The approval broadens the accessibility in the US & advances the QIAGEN’ blood-based test for latent TB detection to support the conversion from the traditional tuberculin skin tests. The companies will continue to work together on the promotion and sale of joint solutions for TB testing 
• LIAISON QuantiFERON-TB Gold Plus is an IGRA technology that was developed by QIAGEN and DiaSorin & is designed to provide streamlined laboratory automation for latent TB screening with a high clinical sensitivity

Ref: Businesswire | Image: Qiagen